These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7723913)

  • 1. Gain in recombinant human erythropoietin dosage with continuous intravenous intradialytic administration for the treatment of anaemia in end-stage renal disease.
    Liani M; Salvati F; Golato M; Cahen R
    Nephron; 1995; 69(2):189. PubMed ID: 7723913
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant human erythropoietin for anaemia in thalassaemia minor patients on dialysis.
    Kagan A; Sinay-Trieman L; Bar-Khayim Y
    Nephrol Dial Transplant; 1995 Dec; 10(12):2375-6. PubMed ID: 8808253
    [No Abstract]   [Full Text] [Related]  

  • 3. Subcutaneous erythropoietin in the treatment of renal anaemia.
    Drinovec J; Varl J
    Przegl Lek; 1992; 49(1-2):38-40. PubMed ID: 1455004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
    Sobota JT
    Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapy of renal anemia with recombinant human erythropoietin].
    Schaefer RM; Kürner B; Zech M; Krahn R; Heidland A
    Dtsch Med Wochenschr; 1988 Jan; 113(4):125-9. PubMed ID: 3276487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin. A new frontier.
    Rutherford C
    J Intraven Nurs; 1991; 14(3):163-5. PubMed ID: 2033478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis.
    Uthayanaka Y; Jirajan B; Krairithichai U; Jantavanich N
    Southeast Asian J Trop Med Public Health; 1993 Sep; 24(3):577-82. PubMed ID: 8160072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of Administration of Erythropoiesis-Stimulating Agents for the Anaemia of End-Stage Kidney Disease in Dialysis.
    Nephrology (Carlton); 2015 Sep; 20(9):663-5. PubMed ID: 26278120
    [No Abstract]   [Full Text] [Related]  

  • 10. Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients.
    Boran M; Dalva I; Yazicioğlu A; Cetin S
    Nephron; 1993; 63(1):113-4. PubMed ID: 8446239
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of once- versus thrice-weekly subcutaneous recombinant human erythropoietin in children receiving continuous cycling peritoneal dialysis.
    Ongkingco JR; Ruley EJ; Turner ME; Fragale MR
    Am J Nephrol; 1994; 14(1):14-8. PubMed ID: 8017476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron in the treatment of anemia in dialysis patients: an important support to erythropoietin.
    Gallieni M
    Int J Artif Organs; 1998 Nov; 21(11):681-6. PubMed ID: 9894741
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of the anaemia of end-stage renal disease with recombinant human erythropoietin.
    Verbeelen D; Hauglustaine D; Sennesael J
    Neth J Med; 1988 Aug; 33(1-2):60-7. PubMed ID: 3247012
    [No Abstract]   [Full Text] [Related]  

  • 14. [The pharmacokinetics of recombinant human erythropoietin].
    Siniukhin VN; Stetsiuk EA; Lovchinskiĭ EV; Lebedev SV; Iarmolinskiĭ IS; Liakhov VV
    Ter Arkh; 1994; 66(8):60-2. PubMed ID: 7985158
    [No Abstract]   [Full Text] [Related]  

  • 15. Ultrapure dialysate reduces dose of recombinant human erythropoietin.
    Schiffl H; Lang SM; Bergner A
    Nephron; 1999; 83(3):278-9. PubMed ID: 10529639
    [No Abstract]   [Full Text] [Related]  

  • 16. [Erythropoietin in renal anemia].
    Peña Amaro MP; García López J; Camacho Romera M
    Rev Enferm; 1992 Mar; 15(163):67-70. PubMed ID: 1565973
    [No Abstract]   [Full Text] [Related]  

  • 17. Correction of the anaemia of chronic renal failure with erythropoietin: pharmacokinetic studies in patients on haemodialysis and CAPD.
    Hughes RT; Cotes PM; Oliver DO; Pippard MJ; Royston P; Stevens JM; Strong CA; Tam RC; Winearls CG
    Contrib Nephrol; 1989; 76():122-30. PubMed ID: 2582777
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of the anaemia of chronic renal failure with recombinant human erythropoietin.
    Winearls CG
    Drugs; 1989 Sep; 38(3):342-5. PubMed ID: 2806134
    [No Abstract]   [Full Text] [Related]  

  • 19. Response to recombinant human erythropoietin (r-Hu EPO) and L-carnitine combination in patients with anemia of end-stage renal disease.
    Boran M; Dalva I; Gönenç F; Cetin S
    Nephron; 1996; 73(2):314-5. PubMed ID: 8773364
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost of treating predialysis patients with recombinant human erythropoietin.
    Durand-Zaleski I; Goldfarb B; Blum-Boisgard C; Drüeke T; Kreis H
    Nephrol Dial Transplant; 1993; 8(4):311-4. PubMed ID: 8390004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.